Pathomation is a leading developer and marketer of Digital Pathology viewing and image management software since 2012. The company firmly believes in the potential of digital pathology in revolutionizing diagnostic consultations, medical education, diagnostic decision support, and ultimately, improving patient care. Their software is designed with a modular approach, catering to a diverse range of user requirements for clinical diagnosis, education, and research.
With a customer base encompassing pharmaceutical companies, teaching institutes, research groups, and clinical pathology labs, Pathomation's software boasts a universal design capable of opening all scanner file formats, with CE-IVD certification for these formats. Moreover, their software is accessible via a web browser without local installation, compatible with both on-premise server and cloud installation, and integrates with third-party Artificial Intelligence algorithms.
In addition to their software portfolio, Pathomation offers Pathotrainer services for biomarker education and training in collaboration with their pathologists’ partner organizations. The company’s dedication to enhancing operational efficiency and aiding in better treatment decisions positions them as a key player in the Information Technology industry.
There is no investment information
No recent news or press coverage available for Pathomation.